Arbutus Biopharma Corporation (ABUS): The patent battle attention is warranted...

Send PM Follow Ignore

Followers	188
Posts	15268
Boards Moderated	1
Alias Born	06/15/2003

aries4747

Re: mick post# 6435

Tuesday, 10/05/2021 10:32:06 AM

Tuesday, October 05, 2021 10:32:06 AM

The patent battle attention is warranted. Seeing it reflected in the price will hopefully be worth the wait.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent ABUS News

Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:31:10 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/23/2026 11:30:44 AM
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:01:31 PM
Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:21:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:01:31 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:34 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:13 AM
Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 12:41:46 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:00:44 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 12:31:34 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 12:31:10 PM
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2025 12:01:34 PM
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 • GlobeNewswire Inc. • 10/07/2025 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2025 01:00:46 PM
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/13/2025 09:40:28 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2025 08:08:29 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2025 08:06:24 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2025 11:32:07 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2025 11:31:30 AM
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/06/2025 11:30:00 AM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent ABUS News

More ABUS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ABUS News

Go Ad-Free